Table of Contents
- Trial overview
- Who can join
- What is being measured
- Trial phase and status
- Trial details
- What this means for readers
Trial overview
The provided trial data does not include a study of 6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE. The only listed trial is NCT06731959, which studies inhaled fexlamose in adults with moderate to severe chronic obstructive pulmonary disease (COPD).[1]
This study is designed to compare the treatment with placebo, which is a look-alike treatment without active medicine.[1]
Who can join
The trial is for adult participants with moderate to severe COPD.[1]
No other eligibility details are given in the provided data, so the age range beyond adulthood, medical rules, and other entry requirements are not available here.
What is being measured
The main endpoint, or main result the study wants to measure, is the change from baseline in prebronchodilator FEV1 at Week 4.[1]
FEV1 is a lung function test that measures how much air a person can blow out in one second. “Prebronchodilator” means the test is done before using a medicine that opens the airways.
Trial phase and status
The study is a Phase 2 trial and its status is Authorised.[1]
Phase 2 trials usually look more closely at whether a treatment may work while continuing safety checks. The provided data does not give more detail about safety results or final outcomes.
Trial details
The study type is interventional, which means researchers give a treatment and then measure the effects.[1]
The planned enrollment is 100 people.[1]
The brief summary says the study aims to evaluate the efficacy of AER-01 compared with placebo.[1]
Interventional means the research team assigns a treatment rather than only observing people.
Efficacy means how well a treatment works in the study.
Placebo helps researchers compare the study treatment against a control that does not contain active medicine.
What this means for readers
Based on the provided data, there is no clinical trial information here for 6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE.[1]
Instead, the available trial record focuses on one lung disease study in adults with COPD, using a Phase 2 design and measuring lung function after 4 weeks.[1]
